Avenue Therapeutics, Inc. ATXI · Stock Open Avenue Therapeutics, Inc. in new tab
Avenue Therapeutics, Inc. Analysis (ATXI)
Is Avenue Therapeutics, Inc. a good investment? Avenue Therapeutics, Inc. (ATXI) is currently trading at 0.3600 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.38. This relatively low multiple may signal that Avenue Therapeutics, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Avenue Therapeutics, Inc. is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -3.14.
Investor FAQ
Does Avenue Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Avenue Therapeutics, Inc.?
Avenue Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of -0.86.
Company Profile
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 23, 2022 | 0.07 |
| April 26, 2024 | 1:100 |
Community Discussion